2.56  0 (0%)		12-08 16:00
Open: 2.56 High: 2.57 Volume: 94,534		Pre. Close: 2.56 Low: 2.53 Market Cap: 77(M)

Short term
Mid term
Targets	6-month :	3.48	1-year :	3.88
Resists	First :	2.98	Second :	3.32
Pivot price	2.68
Supports	First :	2.41	Second :	2
MAs	MA(5) :	2.53	MA(20) :	2.74
	MA(100) :	2.99	MA(250) :	3.05
MACD	MACD :	-0.2	Signal :	-0.2
%K %D	K(14,3) :	20.9	D(3) :	17
RSI	RSI(14): 37.5
52-week	High :	4.84	Low :	2

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ RLMD ] has closed above bottom band by 33.1%. Bollinger Bands are 1.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	2.57 - 2.59	2.59 - 2.6
Low:	2.5 - 2.51	2.51 - 2.53
Close:	2.54 - 2.56	2.56 - 2.59

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

Mon, 04 Dec 2023
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans? - Simply Wall St

Fri, 10 Nov 2023
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2023 Earnings Call Transcript - Yahoo Finance

Wed, 08 Nov 2023
Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results - PR Newswire

Wed, 08 Nov 2023
Relmada Therapeutics Inc (RLMD) Reports Third Quarter 2023 Financial Results - Yahoo Finance

Fri, 03 Nov 2023
Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on ... - Yahoo Finance

Wed, 11 Oct 2023
Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023 - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	30 (M)
Shares Float	23 (M)
Held by Insiders	7.8 (%)
Held by Institutions	60.6 (%)
Shares Short	875 (K)
Shares Short P.Month	701 (K)

EPS	-3.72
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	3.34
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-48.8 %
Return on Equity (ttm)	-83.6 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-77 (M)
Levered Free Cash Flow	-39 (M)

PE Ratio	-0.7
PEG Ratio	0
Price to Book value	0.76
Price to Sales	0
Price to Cash Flow	-1

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.